NEW YORK (GenomeWeb News) – German firm Progen Biotechnik today announced an exclusive distribution agreement covering Germany with Asuragen to offer multiplexed assays based on Asuragen technology.
As a result of the deal, Progen can now offer assays incorporating Asuragen's Signature technology for the detection of mutations found in solid tumors, such as KRAS and BRAF, and fusion transcripts or mutations associated with specific leukemia types and subtypes, Progen said in a statement.
The Cologne-based company now can also offer two state-of-the-art PCR technologies developed by Asuragen for the molecular characterization of trinucleotide repeat in the 5' region of the fragile X mental retardation gene for routine screening, Progen added.
Financial and other terms of the deal were not disclosed.
Last week, Progen also announced a licensing deal with Mikrogen to co-develop, co-manufacture, and co-market multiplexed assays for the Luminex platform. The two companies will further "bundle their activities on equipment and application support" in connection with the Luminex technology, Progen said in a statement.
Under the deal, Mikrogen will concentrate on the routine laboratory market while Progen will concentrate on the research market and technical support and customized testing service markets.
Mikrogen, based in Neuried, Germany, develops diagnostics focused on bacterial, viral, and parasitic infections and autoimmune disorders, according to its website.
Terms of the deal were not disclosed.